Tong Ren Tang Technologies Co Ltd Class H (HK:1666)
:1666
Top Page
Tong Ren Tang Technologies Co
(1666)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$4.50
▲(0.22% Upside)
Action:ReiteratedDate:10/14/25
Tong Ren Tang Technologies Co's overall stock score is primarily influenced by its strong financial performance, despite concerns about declining profitability and cash flow issues. The technical analysis indicates a bearish trend, which is a significant risk. The valuation is reasonable but not enough to outweigh the financial and technical challenges.
Positive Factors
Consistent Revenue Growth
Multi-year revenue growth near 7% demonstrates steady demand for the company’s TCM portfolio and supports durable top-line expansion. Persistent sales growth enables scale benefits, predictable planning, and reinvestment into R&D, distribution and brand-building over the medium term.
Negative Factors
Declining Net Profit Margin
A downward net margin trend signals rising costs, pricing pressure, or mix shifts that compress bottom-line profitability. If persistent, margin erosion reduces retained earnings and free cash generation, limiting capacity to invest, pay dividends, or absorb volatility without altering strategy or cost structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Multi-year revenue growth near 7% demonstrates steady demand for the company’s TCM portfolio and supports durable top-line expansion. Persistent sales growth enables scale benefits, predictable planning, and reinvestment into R&D, distribution and brand-building over the medium term.
Read all positive factors
Tong Ren Tang Technologies Co (1666) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.08B
Dividend Yield4.47%
Average Volume (3M)1.05M
Price to Earnings (P/E)13.1
Beta (1Y)0.84
Revenue Growth0.73%
EPS Growth-34.04%
CountryHK
Employees3,991
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.05
Shares Outstanding628,704,000
10 Day Avg. Volume1,287,300
30 Day Avg. Volume1,053,233
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)0.87
Price to Sales (P/S)0.86
P/FCF Ratio-39.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.45
Revenue Forecast (FY)HK$7.93B
Tong Ren Tang Technologies Co Business Overview & Revenue Model
Company Description
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and f...
How the Company Makes Money
The company generates revenue through multiple key streams, including the sale of traditional Chinese medicinal products, health supplements, and over-the-counter pharmaceuticals. A significant portion of its earnings comes from its extensive dist...
Tong Ren Tang Technologies Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.95B | 7.26B | 6.77B | 5.99B | 5.40B | 4.61B |
| Gross Profit | 2.77B | 2.88B | 2.85B | 2.59B | 2.29B | 2.07B |
| EBITDA | 1.11B | 1.17B | 1.30B | 1.39B | 1.26B | 1.14B |
| Net Income | 431.71M | 521.79M | 590.19M | 582.89M | 507.25M | 467.55M |
Balance Sheet | ||||||
| Total Assets | 14.54B | 14.41B | 13.51B | 12.48B | 11.59B | 10.94B |
| Cash, Cash Equivalents and Short-Term Investments | 5.15B | 4.38B | 4.24B | 4.18B | 3.89B | 3.49B |
| Total Debt | 2.41B | 2.43B | 1.63B | 1.59B | 1.64B | 1.69B |
| Total Liabilities | 4.33B | 4.24B | 3.86B | 3.47B | 3.44B | 3.19B |
| Stockholders Equity | 7.30B | 7.21B | 6.89B | 6.48B | 5.98B | 5.73B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | -158.56M | 450.78M | 565.85M | 877.01M | -110.09M |
| Operating Cash Flow | 1.59B | 15.61M | 554.17M | 723.77M | 1.03B | 435.81M |
| Investing Cash Flow | -116.24M | 1.05B | -1.07B | 43.01M | -197.36M | -195.44M |
| Financing Cash Flow | -634.06M | 288.35M | -497.76M | -499.45M | -474.67M | -164.51M |
Tong Ren Tang Technologies Co Technical Analysis
Negative
4.49
Price Trends
4.25
Negative
4.43
Negative
4.71
Negative
Market Momentum
-0.09
Positive
39.04
Neutral
38.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1666, the sentiment is Negative. The current price of 4.49 is above the 20-day moving average (MA) of 4.11, above the 50-day MA of 4.25, and below the 200-day MA of 4.71, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 39.04 is Neutral, neither overbought nor oversold. The STOCH value of 38.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1666.
Tong Ren Tang Technologies Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$7.37B | 6.31 | 11.90% | 5.80% | -20.64% | -25.39% | |
68 Neutral | HK$5.08B | 13.14 | 5.98% | 4.47% | 0.73% | -34.04% | |
59 Neutral | HK$6.48B | 17.83 | 12.72% | 4.04% | 24.13% | 4.29% | |
57 Neutral | HK$9.02B | 135.64 | 11.21% | ― | 23.37% | ― | |
54 Neutral | HK$9.06B | -28.37 | -1.64% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1666
Tong Ren Tang Technologies Co
3.97
-0.35
-8.02%
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
7.74
-0.32
-3.95%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.80
-0.03
-1.48%
HK:2256
Abbisko Cayman Limited
13.26
6.90
108.49%
HK:2877
China Shineway Pharmaceutical Group Limited
9.76
2.82
40.63%
HK:0723
Reliance Global Holdings Limited
0.23
-0.03
-10.98%
Tong Ren Tang Technologies Co Corporate Events
Tong Ren Tang Technologies Calls EGM to Appoint New Independent Director
Jan 15, 2026
Tong Ren Tang Technologies Co. Ltd. has called an extraordinary general meeting for 6 February 2026 in Beijing to seek shareholder approval for the appointment of Mr. Siu, Paul Yu Hay as an independent non-executive director for the ninth session ...
Tong Ren Tang Technologies Announces Board Reshuffle and Proposed Independent Director Appointment
Jan 13, 2026
Tong Ren Tang Technologies Co. Ltd. has announced that independent non-executive director Li Siu Bun has tendered his resignation from the board, including his roles as chairman of the audit committee and member of the remuneration and strategy an...
Tong Ren Tang Technologies Wins Shareholder Backing for Key Group Agreements and Board Appointment
Dec 30, 2025
Tong Ren Tang Technologies Co. Ltd. announced that shareholders approved all resolutions at an extraordinary general meeting held in Beijing on 30 December 2025. Investors endorsed the renewal of the Distribution Framework Agreement and the Master...
Tong Ren Tang Technologies Sets Out Board Line-Up and Committee Roles
Dec 30, 2025
Tong Ren Tang Technologies Co. Ltd. has announced the current composition of its board of directors, comprising executive, non-executive, independent non-executive and an employee director, with Zhang Yi serving as chairman and Zhang Chun You as g...
Tong Ren Tang Technologies Renews Connected Property Leasing Deal With Controlling Shareholder
Dec 30, 2025
Tong Ren Tang Technologies has renewed its property leasing framework agreement with its ultimate controlling shareholder, Tong Ren Tang Holdings, for a further three-year term from 1 January 2026 to 31 December 2028, covering the lease of product...
Tong Ren Tang Technologies Co Renews Land Use Right Leasing Agreement
Nov 28, 2025
Tong Ren Tang Technologies Co has renewed its Land Use Right Leasing Agreement with Tong Ren Tang Holdings, extending the lease for an additional three years from October 2025 to October 2028. This renewal allows the company to continue its operat...
Tong Ren Tang Technologies Co Revises Trademark Licence Agreement
Nov 28, 2025
Tong Ren Tang Technologies Co has announced a Supplemental Trademark Licence Agreement with Tong Ren Tang Holdings, revising the terms and scope of its Current Trademark Licence Agreement. This includes changes to the subsidiaries entitled to use ...
Tong Ren Tang Technologies Announces EGM to Approve Key Agreements and Board Appointment
Nov 28, 2025
Tong Ren Tang Technologies Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 30, 2025, to approve key agreements and appointments. The company seeks shareholder approval for the renewal of its Distribution Framew...
Tong Ren Tang Technologies Announces Director Change
Nov 28, 2025
Tong Ren Tang Technologies Co. Ltd. announced the resignation of Mr. Chen Fei from his role as a non-executive director due to work adjustments, effective upon the election of a new director by shareholders. The company has proposed Ms. Du Xin as ...
Tong Ren Tang Technologies Co. Announces Key Corporate Developments
Nov 28, 2025
Tong Ren Tang Technologies Co. has announced the proposed renewal of its continuing connected transactions and the appointment of a new director. These developments are set to be discussed at an Extraordinary General Meeting (EGM) scheduled for De...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.